Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases

  • STATUS
    Recruiting
  • End date
    Mar 11, 2025
  • participants needed
    100
  • sponsor
    Yonsei University
Updated on 11 November 2021

Summary

Approximately 40% of colorectal cancer patients will develop colorectal liver metastases (CRLM). The most effective approach to increase long-term survival is CRLM complete resection. Unfortunately, only 10 - 15% of CRLM are initially considered resectable. The objective response rates (ORR) after current first-line systemic chemotherapy (sys-CT) regimens range from 40 to 80% and complete resection rates (CRR) range from 25 to 50% in patients with initially unresectable CRLM. When CRLM patients are not amenable to complete resection after induction of sys-CT, ORRs obtained with second-line sys-CT are much lower (between 10 and 30%) and consequently CRRs are also low (< 10%). Hepatic arterial infusion (HAI) oxaliplatin may represent a salvage therapy in patients with CRLM unresectable after one or more sys-CT regimens with ORRs and CRRs up to 60 and 30%, respectively. This study is designed to evaluate the efficacy of an intensification strategy based on HAI oxaliplatin combined with sys-CT as the first-line treatment in patients with unresectable CRLM.

Details
Condition Metastatic Colorectal Cancer
Treatment intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks, IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks
Clinical Study IdentifierNCT05103020
SponsorYonsei University
Last Modified on11 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically confirmed colorectal cancer (CRC), and radiologic or histologic proof of liver metastasis
Unresectability of the CRLM will be confirmed by a centralized multidisciplinary expert panel (composed of surgeons, radiologists, interventional radiologists and medical oncologists). The panel will review the CT scan and MRI of the patients (weekly web conference). Non-resectability criteria (one of the following criteria)
Upfront R0/R1 resection of all CRLM (that leaves at least two adequately perfused and drained segments) is not possible
Liver metastases in contact with major vessels of the remnant liver which would require resection of the vessel for an R0 resection (i.e., tumor involvement of main portal right and left portal veins, of the three main hepatic veins, or of the retrohepatic vena cava)
At least one measurable liver metastasis according to the RECIST v1.1
Age 18 years
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Life expectancy of at least 3 months
Normal liver function International normalized ratio (INR) <1.5 ULN
Neutrophils >1500/mm
Platelet >100 x 109/L (transfusion allowed)
Hemoglobin >9 g/dL (transfusion allowed)
Bilirubin <1.5 times the upper limit of normal values (ULN)
Aminotransferases <5 ULN, alkaline phosphatase <5 ULN
Calculated creatinine clearance >30 mL/min (Cockcroft and Gault formula)
Urine dipstick for proteinuria of less than 1+ is required within 7 days prior to study entry; if urine dipstick is >= 2+ then a 24 hour urine for protein must demonstrate =< 1 gm of protein in 24 hours to allow participation in the study; NOTE: Urinalysis is also acceptable
Informed consent signed by the patient or his/her legal representative

Exclusion Criteria

Patient eligible for curative-intent treatment of CRLM (i.e. resection and/or thermoablation), according to the local multidisciplinary team and/or the central review. Definitive anatomical contraindication to complete surgical resection (any of the following criteria)
More than two lesions in all liver segments
Bilobar liver metastasis and more than three lesions >3 cm in the hepatic lobe the least affected (i.e. the future remnant liver)
Bilobar liver metastasis and disease liver extend >50%
Extrahepatic tumor disease (except 3 lung nodules <10 mm deemed amenable to curative-intent resection/thermoablation and non-resected primary tumor with no or mild symptoms)
Major surgical procedure within 28 days prior to study treatment start, or patients who have not fully recovered from major surgery
Radiotherapy to target lesion within 4 weeks before the study (A 2-week washout is permitted for palliative radiation.)
Has known uncontrolled active CNS metastases and/or carcinomatous meningitis
Peripheral neuropathy CTCAE v4.03 grade 2
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
Note: Participants with (A) basal cell carcinoma of skin, (B) squamous cell
carcinoma of the skin, (C) low grade thyroid cancer or carcinoma in situ (eg
cervical cancer in situ) that have undergone potentially curative therapy are
not excluded
\. Has an active autoimmune disease that has required systemic treatment in
the past 2 years. Replacement therapy, such as thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary
insufficiency, is not considered a form of systemic systemic treatment and is
allowed
\. Uncontrolled hypertension or clinically active cardiovascular disease: for
example, cerebrovascular accident or transient ischemic attack, unstable
angina, myocardial infarction within 24 weeks prior to randomization. Have
symptomatic congestive heart failure (CHF; New York Heart Association II-IV)
or symptomatic or poorly controlled cardiac arrhythmia
\. Have significant bleeding disorders, or evidence of bleeding diathesis or
coagulopathy
\. Have had a significant bleeding episode from the gastrointestinal (GI)
tract or lung
\. Have a history of GI perforation and/or fistula, or intra-abdominal
abscess within 24 weeks prior to randomization
\. Have a history of HNPCC syndrome or polyposis
\. Have experienced any arterial thromboembolic event or ongoing treatment
with anticoagulants for therapeutic purpose within 24 weeks prior to
randomization
\. Has a known history of human immunodeficiency virus (HIV) infection
\. Are pregnant or breast feeding. Females of childbearing potential must
have a negative serum or urine pregnancy test within 7 days prior to first
dose of study treatment. For women of childbearing potential and men
agreement to remain abstinent or use contraceptive methods that result in a
failure rate of <1% per year during the treatment period and for at least 30
days after the last dose of study drugs. Postmenopausal women is defined that
1) must have been amenorrheic for at least 12 months, > 50 years old or 2)
Age 50 years old and amenorrheic for 12 or more months in the absence of
chemotherapy, tamoxifen, toremifene, or ovarian suppression and follicle-
stimulating hormone (FSH) and estradiol in the postmenopausal range (>40
mIU/mL), 3) prior bilateral oophorectomy
\. Patients who are hypersensitive reaction to experimental drugs
\. Patients who are hypersensitive to CHO cell products or other recombinant
or humanized antibodies
\. In case of contraindication of experimental drugs
\. Have any condition (eg, psychological, geographical, or medical) that
does not permit compliance with the study and follow-up procedures or suggest
that the patient is, in the investigator's opinion, not an appropriate
candidate for the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note